What Is 503A Compounding, and Why It Matters for Compounded Tirzepatide

As of March 19, 2025, the FDA ended enforcement discretion for 503B outsourcing facilities producing compounded tirzepatide, leaving Section 503A as the only remaining legal compounded pathway for the drug. The U.S. District Court for the Northern District of Texas affirmed the agency's authority on May 7, 2025 in Outsourcing Facilities Association v. FDA, foreclosing the principal industry challenge.

That ruling made one provision of the Federal Food, Drug, and Cosmetic Act suddenly load-bearing for every patient on a compounded GLP-1. 503A compounding refers to 21 USC § 353a, the statute governing patient-specific compounding by state-licensed pharmacies. What follows is what 503A requires, how it differs from its sibling Section 503B, what "personalized" tirzepatide means under the statute, and how a patient can read a pharmacy's compliance posture before their next refill. Patients comparing options can also consult providers ranked by 503A compliance for a side-by-side audit.

What Section 503A Actually Says

Section 503A is 21 USC § 353a, added to the Federal Food, Drug, and Cosmetic Act by the FDA Modernization Act of 1997 and tightened by the Drug Quality and Security Act of 2013 (DQSA). DQSA was Congress's response to the New England Compounding Center fungal meningitis outbreak, which infected 753 people and killed 64 from contaminated steroid injections shipped from a single Massachusetts pharmacy.

The statute exempts a compounded preparation from three central FDCA requirements: new drug approval under section 355, adequate-directions-for-use labeling under section 352(f)(1), and current good manufacturing practice (cGMP) under section 351(a)(2)(B). Those exemptions exist only if every condition below is met:

Compounded by a licensed pharmacist or physician, in a state-licensed pharmacy, by or under the supervision of a licensed pharmacist.
Bulk drug substances sourced from FDA-registered suppliers, meeting USP or National Formulary standards, with valid certificates of analysis.
Compounded for an identified individual patient on receipt of a valid prescription, or in limited anticipatory quantities documented by a prior prescriber relationship.
Not "essentially a copy of a commercially available drug product," unless the prescriber documents a change producing "a significant difference" for that specific patient.
Not on the FDA's "difficult to compound" list and not withdrawn from the market for safety or effectiveness reasons.
No more than 5% of total prescriptions dispensed across state lines, absent a memorandum of understanding between the state and the FDA.

Falling outside any one of these conditions moves the pharmacy from 503A into a category the FDA treats as an unregistered manufacturer, the public-safety problem DQSA was written to address.

What 503A Is Not: The Brief Contrast With 503B

Section 503A's sibling, Section 503B, was created by the same 2013 DQSA but covers a different operating model. The two are often blurred in marketing copy, and the distinction matters when a patient evaluates the reassurances on a telehealth landing page.

A 503A pharmacy is state-licensed, compounds for a specific named patient under a valid prescription, is inspected primarily by the state board of pharmacy, and must comply with USP chapters <795> (non-sterile), <797> (sterile), and where applicable <800> (hazardous drugs). It is not subject to cGMP.

A 503B outsourcing facility, by contrast, is registered directly with the FDA, may compound without patient-specific prescriptions (typically for hospital and clinic office stock), must comply with full cGMP under 21 CFR Parts 210 and 211, and is subject to risk-based FDA inspection.

Both designations are legal. Neither is a quality grade on its own. They serve different supply chains, and as of March 2025, only 503A can supply patient-specific compounded tirzepatide to an individual patient.

Why 503A Matters for Tirzepatide After March 2025

Until late 2024, both 503A pharmacies and 503B outsourcing facilities were compounding tirzepatide under FDA enforcement discretion granted while the drug sat on the agency's official shortage list. That window has now closed. The relevant dates are tightly clustered:

October 2024: FDA initially declared the tirzepatide shortage resolved.
December 19, 2024: Tirzepatide was formally removed from the FDA Drug Shortages list after the agency reaffirmed its determination.
March 5, 2025: The U.S. District Court for the Northern District of Texas denied the Outsourcing Facilities Association's motion for a preliminary injunction.
March 10, 2025: Enforcement deadline took effect for 503A pharmacies that had been relying on shortage status.
March 19, 2025: Enforcement deadline took effect for 503B outsourcing facilities.
May 7, 2025: The same court issued a full ruling in Outsourcing Facilities Association v. FDA, No. 4:25-cv-00132, finding the FDA "acted within its statutory authority in determining that tirzepatide was no longer in shortage."

The substantive consequence is twofold. 503B facilities can no longer compound tirzepatide as essentially-a-copy of Mounjaro or Zepbound, because the shortage exception that previously permitted batch production has closed. 503A pharmacies can compound tirzepatide only for a specific named patient where the prescriber has documented a clinical need the commercially available product does not meet. That is the "significant difference" provision of 21 USC § 353a, applied to a drug that exists commercially in approved form.

Compounded tirzepatide today must be a personalized formulation written for an individual patient. A generic "compounded GLP-1" product line, identical across thousands of customers, does not fit inside the statute as the FDA now reads it. What "personalized" actually looks like is the next question.

What "Personalized" Means in Practice for Compounded Tirzepatide

The "personalized" language on compounded tirzepatide websites is doing real legal work. It bridges Section 503A's "no copies" rule and the fact that tirzepatide exists commercially as Mounjaro and Zepbound. Without that bridge, the compound is a copy and the exemption collapses.

The statute permits compounding of a would-be copy when the prescriber documents a change that "will produce a significant difference for the patient." Most implementations combine tirzepatide with another active or excipient. Public formulation data and litigation filings name three additives:

Pyridoxine HCl (vitamin B6): referenced in several compounders' formulation pages, typically 5 to 30 mg per injection alongside tirzepatide near 17 mg/mL.
Niacinamide (vitamin B3): Empower Pharmacy publishes a 17 mg/mL tirzepatide / 2 mg/mL niacinamide formulation, available "exclusively through our 503A compounding pharmacy pursuant to a patient-specific prescription."
Glycine: named in litigation against Strive Pharmacy as a stabilizer-and-additive justification for the same combination product.

This is contested ground. Eli Lilly has sued several 503A compounders, including Strive in Lilly v. Strive, No. 1:25-cv-00401, D. Del., and Empower in Lilly v. Empower, No. 2:25-cv-02183, D.N.J., plus four telehealth companies (Mochi, Fella, Henry Meds, Willow), arguing that adding a B-vitamin to mass-produced vials does not make a formulation "personalized" and amounts to deceptive trade practice. The arc is summarized in Lilly's lawsuits against compounders. The FDA has expressed parallel skepticism in 2025-2026 warning letters, calling phrases like "generic" and "clinically proven" misleading.

A personalized-formulation claim is legally meaningful only if a prescriber wrote a patient-specific prescription documenting a clinical reason for the additive. A formulation prepared identically for thousands of patients, justified only by a vitamin, is on contested legal ground. For the patient-side workflow, see how to get prescribed compounded tirzepatide in 2026.

Signs of Solid 503A Compliance

A patient does not need legal training to verify a 503A pharmacy. The statute's conditions translate into four checks, completable in under fifteen minutes from a phone.

1. The pharmacy is named, not hidden. The label and the telehealth provider's website should both name the dispensing pharmacy by legal name and street address. A site that refers only to "our trusted compounding partner" fails this check. Every legitimate 503A pharmacy is licensed under a state board of pharmacy, and that license is public record.

2. The license is verifiable in the patient's state. The pharmacy must be licensed in the state where the patient resides, not only its home state, to legally ship there. State board lookups are public; NABP also maintains a Verified Pharmacy Program search at nabp.pharmacy.

3. The pharmacy holds at least one voluntary accreditation. The three meaningful programs are PCAB (administered by ACHC, public lookup at organization.achc.org), URAC, and NABP's Compounding Pharmacy Accreditation. Fewer than 1% of U.S. pharmacies hold PCAB. Earning one subjects the pharmacy to USP <795>, <797>, and <800> audits.

4. There is no recent FDA warning letter. The FDA publishes warning letters at letters.fda.gov. A name search returns any issued; a letter within the last two years is the strongest negative signal a non-specialist can find.

The same checklist applies whether the prescription was written through telehealth intake or by a patient's own physician.

Red Flags That Suggest Weak 503A Compliance

The same statutory conditions produce a recognizable failure pattern when a pharmacy operates outside them.

The pharmacy is hidden behind the brand. A telehealth website marketing a "compounded GLP-1" product without naming the dispensing pharmacy is selling on the brand's reputation, not the pharmacy's compliance record.
No state license traceable. State boards return no active license under the named pharmacy, or a license under a different entity the website does not disclose.
No voluntary accreditation. Absence of PCAB, ACHC, URAC, or NABP listing is not disqualifying alone, but it is cumulative with the other signals.
Identical formulation marketed to every patient. A single "compounded tirzepatide" product page sold the same way to every customer, with no individualized prescriber documentation, indicates a generic-supply model that struggles to meet 503A's patient-specific requirement.
A recent FDA warning letter on file. In January 2026, the FDA issued a warning letter to Boothwyn Pharmacy citing sterility failures. Findings included a semaglutide product released at 79.9% of labeled potency (USP requires 90 to 110%) and 23 of 23 out-of-specification investigations completed without following the pharmacy's own SOPs. Tirzepatide that failed sterility testing was also distributed.
Marketing calling compounded tirzepatide "generic" or "FDA approved." The FDA flagged both phrasings in 2025-2026 warning letters, including a September 9, 2025 batch of more than 55 letters to GLP-1 online sellers.

A pharmacy missing one signal is not necessarily problematic; one missing several is operating outside the 503A frame. Complaint patterns through BBB complaint patterns and cold-chain handling records sharpen the picture.

Where to Go From Here

Section 503A compliance is the single most important regulatory lens for evaluating a compounded tirzepatide provider in 2026, because it is the only legal pathway that remains. The statute is specific, the verification tools are public, and the failure pattern is documented in active enforcement records.

Two next steps follow. Run the four-check verification on the pharmacy currently dispensing the prescription; the longer version is laid out in how to verify your specific pharmacy. Then compare providers on this axis rather than on price; providers ranked by 503A compliance presents that comparison as an audit rather than a marketing list.

FAQ

Is compounded tirzepatide from a 503A pharmacy FDA-approved?

No. Compounded medications are not FDA-approved or FDA-reviewed for safety and efficacy. A 503A pharmacy operates under a federal compounding exemption in 21 USC § 353a, which permits patient-specific compounding without going through the new-drug-approval process. The resulting compound is not an approved drug, and the prescriber and pharmacy bear responsibility for that specific patient's preparation.

Can a 503A pharmacy still legally compound tirzepatide in 2026?

Yes, but only under narrower conditions than before. Since the FDA's March 2025 enforcement actions, a 503A pharmacy can compound tirzepatide only on a valid patient-specific prescription where the prescriber has documented a clinical reason the commercially available product (Mounjaro or Zepbound) does not meet that specific patient's needs. Generic, identical compounded tirzepatide marketed to every customer no longer falls within the statute as the FDA now reads it.

What is the difference between 503A and 503B for compounded tirzepatide specifically?

After the March 19, 2025 FDA enforcement deadline, 503B outsourcing facilities can no longer compound tirzepatide under the prior shortage-based exception. 503A, which is patient-specific and state-licensed, is the only remaining legal compounded pathway. 503A pharmacies are state-regulated and are not required to comply with FDA cGMP regulations, while 503B facilities are FDA-registered and must comply with 21 CFR Parts 210 and 211.

How do I know if my 503A pharmacy is FDA-compliant?

Three fast checks. First, the pharmacy must be named on the provider's site and traceable to an active state-board-of-pharmacy license in the patient's own state. Second, look for at least one voluntary accreditation: PCAB through ACHC, URAC, or NABP's Compounding Pharmacy Accreditation. Third, search letters.fda.gov for the pharmacy's name; a recent FDA warning letter is the strongest negative signal a patient can find without legal training.